AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8100911 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine given at closure of the peritoneum (iv post)
Number of subjects: 60
Study 3520204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cianidanol (1.5 g daily for 2 weeks, then 2.25 g for 14 weeks)
Number of subjects: 338
Study 3520204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 3520204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cianidanol
Number of subjects: 338
Study 30346977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored model for hierarchical inference
Number of subjects: 0
Study 30346977 — intervention group
Group type: COMPARATOR
Intervention: Generically powerful variational method for hierarchical inference
Number of subjects: 0
Study 27883319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 22
Study 27883319 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (combined with HRT)
Number of subjects: 22
Study 27883319 — intervention group
Group type: COMPARATOR
Intervention: Walking (placebo group)
Number of subjects: 22
Study 27883319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HRT and walking
Number of subjects: 22
Study 24337601 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging combined with comprehensive lifestyle modification
Number of subjects: 1300
Study 22958678 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurse-GP partnership care
Number of subjects: 0
Study 22958678 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 20980048 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1
Number of subjects: 900
Study 20980048 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 900
Study 20980048 — intervention group
Group type: COMPARATOR
Intervention: tOPV
Number of subjects: 900
Study 20980048 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 900
Study 20980048 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV3
Number of subjects: 900
Study 17396068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (CC)
Number of subjects: 0
Study 15567534 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder impingement group during lead limb transfer
Number of subjects: 23
Study 15567534 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder impingement group during trail limb transfer
Number of subjects: 23
Study 15567534 — intervention group
Group type: COMPARATOR
Intervention: No shoulder impingement group during lead limb transfer
Number of subjects: 23
Study 12032013 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (n = 48)
Number of subjects: 93
Study 12032013 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 45)
Number of subjects: 93
Study 10461716 — intervention group
Group type: EXPERIMENTAL
Intervention: Head positioned on the down-side
Number of subjects: 39
Study 10461716 — intervention group
Group type: COMPARATOR
Intervention: Head positioned on the up-side
Number of subjects: 39
Study 7604380 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) in patients with sepsis
Number of subjects: 8
Study 7604380 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) in ambulatory patients receiving HPN
Number of subjects: 8
Study 1970738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-morphine mixture (0.125% bupivacaine with morphine 0.05 mg kg‐1)
Number of subjects: 30
Study 1970738 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (0.125% bupivacaine)
Number of subjects: 30
Study 1970738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bupivacaine-morphine mixture and Bupivacaine alone)
Number of subjects: 30
Study 396690 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin 1.5 g daily
Number of subjects: 25
Study 396690 — intervention group
Group type: COMPARATOR
Intervention: ampicillin 4 g daily
Number of subjects: 25
Study 31486447 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol per day
Number of subjects: 56
Study 29106881 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal post-operative instructions
Number of subjects: 99
Study 29106881 — intervention group
Group type: EXPERIMENTAL
Intervention: Video teaching tool along with standard verbal instructions
Number of subjects: 99
Study 29106881 — intervention group
Group type: EXPERIMENTAL
Intervention: Video teaching tool only
Number of subjects: 99
Study 26499867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively challenging mobility exercise program for 6 weeks
Number of subjects: 0
Study 26499867 — intervention group
Group type: COMPARATOR
Intervention: Group education program for 6 weeks
Number of subjects: 0
Study 23993887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Number of subjects: 30
Study 23993887 — intervention group
Group type: COMPARATOR
Intervention: No salpingectomy
Number of subjects: 30
Study 21247627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane alone (25 mg once a day, orally)
Number of subjects: 9779
Study 21247627 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment (tamoxifen 20 mg once a day, orally for 5 years followed by exemestane)
Number of subjects: 9779
Study 21247627 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 9779
Study 21247627 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane alone
Number of subjects: 9779
Study 19930904 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Ulinastatin plus Thymosin‐alpha(1)
Number of subjects: 70
Study 19930904 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (antibiotics and fluid resuscitation)
Number of subjects: 70
Study 18046737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness Game (experimental intervention)
Number of subjects: 28
Study 18046737 — intervention group
Group type: COMPARATOR
Intervention: Non-legal programming (control intervention)
Number of subjects: 28
Study 15917722 — intervention group
Group type: EXPERIMENTAL
Intervention: HESA‐A (50 mg/kg/day)
Number of subjects: 24
Study 15917722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12684572 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with antioxidant vitamins and minerals at nutritional doses
Number of subjects: 13535
Study 12684572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13535
Study 10593774 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 48
Study 10593774 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 48
Study 8910181 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100
Study 8910181 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 100
Study 8910181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthesia types
Number of subjects: 100
Study 1817626 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine 45 ml (168.75 mg) with adrenaline 1 in 200,000
Number of subjects: 22
Study 1817626 — intervention group
Group type: COMPARATOR
Intervention: Plain solution (bupivacaine without adrenaline)
Number of subjects: 22
Study 7183202 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 32
Study 7183202 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 32
Study 30607986 — intervention group
Group type: EXPERIMENTAL
Intervention: Precast adjustable compression system
Number of subjects: 42
Study 30607986 — intervention group
Group type: COMPARATOR
Intervention: Multilayered compression bandages
Number of subjects: 42
Study 28883183 — intervention group
Group type: EXPERIMENTAL
Intervention: handoverEHR (electronic handover tool)
Number of subjects: 32
Study 25469463 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 or 20 μg/day)
Number of subjects: 122
Study 25469463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 24705731 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvarado score (group A)
Number of subjects: 269
Study 24705731 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgment (group B)
Number of subjects: 269
Study 23021465 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the tonsillar fossa using 3‐0 chromic sutures on tapered needles.
Number of subjects: 763
Study 23021465 — intervention group
Group type: COMPARATOR
Intervention: Tonsillar fossa left open (control group).
Number of subjects: 763
Study 23021465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillar fossa closed.
Number of subjects: 763
Study 19598336 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsupialization
Number of subjects: 212
Study 19598336 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate application
Number of subjects: 212
Study 17464256 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted diagnosis (CAD)
Number of subjects: 30
Study 17464256 — intervention group
Group type: COMPARATOR
Intervention: Without CAD (combined readings of radiologists)
Number of subjects: 30
Study 15257046 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg on days 0 and 10 after transplantation; steroid-free group n=186)
Number of subjects: 364
Study 15257046 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (0.3 mg/kg per day tapered to 0 mg at week 16 after transplantation; steroids group n=178)
Number of subjects: 364
Study 15257046 — intervention group
Group type: COMPARATOR
Intervention: Comparison of steroid-free versus steroids at 3 months
Number of subjects: 364
Study 15257046 — intervention group
Group type: COMPARATOR
Intervention: Comparison of steroid-free versus steroids at 12 months
Number of subjects: 364
Study 12510471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding (PV)
Number of subjects: 19
Study 12510471 — intervention group
Group type: COMPARATOR
Intervention: Usual care attention control
Number of subjects: 19
Study 12510471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding (PV) after crossover
Number of subjects: 19
Study 9525435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir 5 mg/kg once weekly for 2 weeks, then maintenance therapy with 5 mg/kg once every other week
Number of subjects: 150
Study 9525435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir 3 mg/kg once every other week
Number of subjects: 150
Study 9525435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir therapy
Number of subjects: 150
Study 9525435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 150
Study 7893034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of clonidine per os (PO)
Number of subjects: 15
Study 7893034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg) and vecuronium (0.15 mg/kg)
Number of subjects: 15
Study 7893034 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3.6% to 11%)
Number of subjects: 15
Study 2305060 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-screen workstation (1,000-line monitors, 12-bit dynamic range)
Number of subjects: 4
Study 2305060 — intervention group
Group type: COMPARATOR
Intervention: Film panel alternator
Number of subjects: 4
Study 344899 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 191827
Study 344899 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 191827
Study 31668003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 35
Study 31668003 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment and microdermabrasion
Number of subjects: 35
Study 31668003 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (placebo)
Number of subjects: 35
Study 30912222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d
Number of subjects: 460
Study 30912222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 460
Study 30912222 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/d
Number of subjects: 460
Study 30912222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 28922397 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light exposure (n = 12)
Number of subjects: 30
Study 28922397 — intervention group
Group type: COMPARATOR
Intervention: Amber light exposure (n = 18)
Number of subjects: 30
Study 25583753 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Number of subjects: 80
Study 25583753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23106511 — intervention group
Group type: EXPERIMENTAL
Intervention: FDIS+metronidazole
Number of subjects: 184
Study 23106511 — intervention group
Group type: COMPARATOR
Intervention: FDIS+placebo
Number of subjects: 184
Study 23106511 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+metronidazole
Number of subjects: 184
Study 23106511 — intervention group
Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 184
Study 20808147 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative reactivation and rehabilitation (IRR)
Number of subjects: 168
Study 20808147 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 168
Study 19968048 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 12
Study 19968048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16715687 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration regimen (60 mg per day tapered over 12 weeks)
Number of subjects: 334
Study 16715687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose regimen (30 mg per day tapered over 20 weeks)
Number of subjects: 334
Study 16715687 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose regimen (60 mg per day tapered over 20 weeks)
Number of subjects: 334
Study 15478760 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity judgment task with large numbers
Number of subjects: 0
Study 15478760 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity judgment task with small numbers
Number of subjects: 0
Study 15478760 — intervention group
Group type: COMPARATOR
Intervention: Number magnitude judgment task
Number of subjects: 0
Study 11547070 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic infiltration with 1% lidocaine
Number of subjects: 150
Study 11547070 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal instillation of 2% lidocaine gel
Number of subjects: 150
Study 9337437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous‐to‐oral ofloxacin
Number of subjects: 89
Study 9337437 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous‐to‐oral switch therapy
Number of subjects: 89
Study 9337437 — intervention group
Group type: COMPARATOR
Intervention: Standard switch therapy
Number of subjects: 89
Study 9337437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ofloxacin therapy
Number of subjects: 89
Study 7835811 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery
Number of subjects: 99
Study 7835811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (adjuvant treatment)
Number of subjects: 99
Study 7835811 — intervention group
Group type: COMPARATOR
Intervention: 32P (adjuvant treatment)
Number of subjects: 99
Study 7835811 — intervention group
Group type: COMPARATOR
Intervention: Observation (adjuvant treatment)
Number of subjects: 99
Study 3680564 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) dextromethorphan (DM) suspension 60 mg bid
Number of subjects: 24
Study 3680564 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) DM solution 30 mg qid
Number of subjects: 24
Study 31786954 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk muscle endurance (measured by Timed Loaded Standing Test)
Number of subjects: 31
Study 29343507 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 219
Study 29343507 — intervention group
Group type: COMPARATOR
Intervention: apremilast
Number of subjects: 219
Study 26787794 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming (n=78)
Number of subjects: 160
Study 26787794 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive heating (n=82)
Number of subjects: 160
Study 25910532 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (0.4 μg/kg per minute) and ketamine (5 μg/kg per minute)
Number of subjects: 56
Study 25910532 — intervention group
Group type: COMPARATOR
Intervention: remifentanil (0.4 μg/kg per minute) and saline solution
Number of subjects: 56
Study 22981952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony‐forming units), n = 40, orally, in 5 drops, 1 time daily, for 21 days
Number of subjects: 80
Study 22981952 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 40, orally, in 5 drops, 1 time daily, for 21 days
Number of subjects: 80
Study 20350523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg at 12 h pre-PCI and 40 mg at 2 h pre-PCI, followed by atorvastatin 40 mg/day for 30 days post-PCI
Number of subjects: 350
Study 20350523 — intervention group
Group type: COMPARATOR
Intervention: Usual care including atorvastatin 40 mg/day for 30 days post-PCI
Number of subjects: 350
Study 18218826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration exercise training (VIB) group
Number of subjects: 30
Study 18218826 — intervention group
Group type: COMPARATOR
Intervention: Exercise without vibration training (EX) group
Number of subjects: 30
Study 16830258 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQL scores > median
Number of subjects: 0
Study 16830258 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week change in HRQL > median
Number of subjects: 0
Study 16830258 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in FACT-P Grand Total Score > median
Number of subjects: 0
Study 16830258 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline or 12-week change in HRQL
Number of subjects: 0
Study 16830258 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater deterioration in HRQL
Number of subjects: 0
Study 12860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum positive cultures (>10(5) cfu/ml) in endometritis patients (39% of 67 patients)
Number of subjects: 97
Study 12860331 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without endometritis)
Number of subjects: 97
Study 12860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of parvo biovar
Number of subjects: 97
Study 12454514 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 269
Study 12454514 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 269
Study 9800017 — intervention group
Group type: EXPERIMENTAL
Intervention: Video teaching
Number of subjects: 16
Study 9800017 — intervention group
Group type: COMPARATOR
Intervention: Lecture accompanied by slides
Number of subjects: 16
Study 8181026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonglycosidic adrenergic and nonadrenergic inotropic drugs
Number of subjects: 0
Study 8181026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonglycosidic inotropic drugs (vesnarinone and ibopamine)
Number of subjects: 0
Study 8181026 — intervention group
Group type: COMPARATOR
Intervention: Adrenergic agents and phosphodiesterase inhibitors
Number of subjects: 0
Study 2659235 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin and amikacin
Number of subjects: 0
Study 2659235 — intervention group
Group type: COMPARATOR
Intervention: Imipenem and placebo
Number of subjects: 0
Study 4938244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopropazate
Number of subjects: 23
Study 4938244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31849248 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 0
Study 28666080 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate)
Number of subjects: 293
Study 28666080 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a reduced frequency (200 mg every 4 weeks plus MTX)
Number of subjects: 293
Study 28666080 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (CZP stopped)
Number of subjects: 293
Study 28666080 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a standard dose
Number of subjects: 293
Study 28666080 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) at a reduced frequency
Number of subjects: 293
Study 25607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 150
Study 25607594 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 150
Study 23328304 — intervention group
Group type: COMPARATOR
Intervention: 4-galactosylxylose (gaxilose) at doses of 0.45 g for urine tests and 2.7 g for blood tests
Number of subjects: 42
Study 23328304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20549321 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (TA1) 3.2 mg twice per day for 7 days
Number of subjects: 24
Study 20549321 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for SAP
Number of subjects: 24
Study 18654774 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐midvastus approach
Number of subjects: 70
Study 18654774 — intervention group
Group type: COMPARATOR
Intervention: medial parapatellar arthrotomy
Number of subjects: 70
Study 17448266 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium with or without vitamin D therapy
Number of subjects: 0
Study 17448266 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D therapy
Number of subjects: 0
Study 17448266 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen, selective estrogen receptor modulators (SERMs), and bisphosphonates (when given in combination with calcium and vitamin D)
Number of subjects: 0